TG Therapeutics (TGTX) Expected to Announce Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) will likely be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.38 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

TG Therapeutics Stock Up 0.2%

Shares of NASDAQ:TGTX opened at $29.53 on Monday. The firm’s 50 day moving average price is $29.90 and its 200 day moving average price is $31.37. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of 10.62 and a beta of 1.85. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TGTX shares. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. lowered their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. B. Riley Financial upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $50.00.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently modified their holdings of TGTX. Invesco Ltd. increased its holdings in shares of TG Therapeutics by 47.1% in the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock valued at $47,989,000 after acquiring an additional 515,481 shares during the period. Corient Private Wealth LLC boosted its stake in TG Therapeutics by 3.6% during the 4th quarter. Corient Private Wealth LLC now owns 41,764 shares of the biopharmaceutical company’s stock worth $1,245,000 after purchasing an additional 1,469 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in TG Therapeutics during the 4th quarter worth $212,000. Empowered Funds LLC acquired a new position in TG Therapeutics in the fourth quarter valued at $1,698,000. Finally, nVerses Capital LLC purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at about $250,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.